Fusion Antibodies – argues some “excellent progress”… so why has the covid bandwagon currently de-railed somewhat here?
By Steve Moore | Monday 6 July 2020
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Fusion Antibodies (FAB) has updated with CEO Paul Kerr emphasising “distributor agreements will broaden our reach in two key markets” and “generated a panel of SARS-CoV-2 S antigens”. The covid bandwagon has though currently de-railed somewhat here – the shares presently back below 90p, down 14%...
You must be a registered member to read this story
ShareProphets is reader-supported journalism
Join us for free and gain access to three articles per month
Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.